[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002214854A1 - Lipid formulations for target delivery - Google Patents

Lipid formulations for target delivery

Info

Publication number
AU2002214854A1
AU2002214854A1 AU2002214854A AU1485402A AU2002214854A1 AU 2002214854 A1 AU2002214854 A1 AU 2002214854A1 AU 2002214854 A AU2002214854 A AU 2002214854A AU 1485402 A AU1485402 A AU 1485402A AU 2002214854 A1 AU2002214854 A1 AU 2002214854A1
Authority
AU
Australia
Prior art keywords
target delivery
lipid formulations
lipid
active agent
systemic delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214854A
Inventor
Pieter R. Cullis
David B. Fenske
Ian Maclachlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Inex Pharmaceuticals Corp
Original Assignee
University of British Columbia
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Inex Pharmaceuticals Corp filed Critical University of British Columbia
Publication of AU2002214854A1 publication Critical patent/AU2002214854A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides lipid-based systemic delivery vehicles and method for selectively targeting an active agent to a specific tissue site. The methods include designing a lipid-based systemic delivery vehicle having a plurality of constitutent parts, and thereafter varying the amounts of each of the plurality of constituent parts to impart tissue selectivity. After tissue selectivity is imparted it is possible to selectively target an active agent to a specific tissue site.
AU2002214854A 2000-10-25 2001-10-25 Lipid formulations for target delivery Abandoned AU2002214854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24318500P 2000-10-25 2000-10-25
US60/243,185 2000-10-25
PCT/CA2001/001513 WO2002034236A2 (en) 2000-10-25 2001-10-25 Lipid formulations for target delivery

Publications (1)

Publication Number Publication Date
AU2002214854A1 true AU2002214854A1 (en) 2002-05-06

Family

ID=22917671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214854A Abandoned AU2002214854A1 (en) 2000-10-25 2001-10-25 Lipid formulations for target delivery

Country Status (7)

Country Link
EP (1) EP1328254B1 (en)
JP (1) JP2004511572A (en)
AT (1) ATE354350T1 (en)
AU (1) AU2002214854A1 (en)
CA (1) CA2426244A1 (en)
DE (1) DE60126801T2 (en)
WO (1) WO2002034236A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1519714T3 (en) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Method and apparatus for preparing liposomes
NZ544637A (en) * 2003-07-16 2010-04-30 Protiva Biotherapeutics Inc Lipid encapsulated interfering RNA
CN1968714B (en) 2004-05-05 2013-10-16 赛伦斯治疗公司 Lipids, lipid complexes and use thereof
WO2006069782A2 (en) 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use
CA2569645C (en) 2004-06-07 2014-10-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
JP4796062B2 (en) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド Lipid-encapsulating interfering RNA
JP2008504827A (en) * 2004-07-02 2008-02-21 プロチバ バイオセラピューティクス インコーポレイティッド Immunostimulatory siRNA molecules and methods of use thereof
EP2199298A1 (en) * 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
AU2005316213C1 (en) * 2004-12-16 2011-08-25 Protech Research Pty Ltd Transfer of molecules
WO2006063411A2 (en) * 2004-12-16 2006-06-22 Protech Research Pty Ltd Transfer of molecules
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
CN102321626B (en) 2006-07-21 2014-12-10 赛伦斯治疗有限公司 Means for inhibiting the expression of protein kinase 3
WO2008074487A2 (en) 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
KR20160029866A (en) 2007-05-25 2016-03-15 더 유니버시티 오브 브리티쉬 콜롬비아 Formulations for the oral administration of therapeutic agents and related methods
JP2011506432A (en) * 2007-12-10 2011-03-03 エピターゲット・アーエス Acoustically sensitive drug delivery particles containing non-lamellar-forming lipids
ES2638448T3 (en) 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid administration
CN102245590B (en) 2008-10-09 2014-03-19 泰米拉制药公司 Improved amino lipids and methods for the delivery of nucleic acids
CN102203618B (en) 2008-10-30 2014-10-15 郭培宣 Membrane-integrated viral dna-packaging motor protein connector biosensor for DNA sequencing and other uses
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000108A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, compositions comprising the same and uses thereof
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
LT3338765T (en) 2009-12-01 2019-06-25 Translate Bio, Inc. Steroid derivative for the delivery of mrna in human genetic diseases
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
ME03491B (en) 2011-06-08 2020-01-20 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nuclease resistant polynucleotides and uses thereof
AU2014215421A1 (en) 2013-02-05 2015-08-13 1Globe Health Institute Llc Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
KR20150128687A (en) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. Methods for purification of messenger rna
BR112015022868B1 (en) 2013-03-14 2023-05-16 Ethris Gmbh CFTR MRNA COMPOSITIONS AND RELATED USES AND METHODS
JP2016175841A (en) * 2013-08-02 2016-10-06 三郎 斎藤 Liposome, and vaccine composition that induces cytotoxic t lymphocyte activity
MX2016005239A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Mrna therapy for phenylketonuria.
ES2954366T3 (en) 2013-10-22 2023-11-21 Translate Bio Inc Messenger Ribonucleic Acid Therapy for Argininosuccinate Synthetase Deficiency
DK3594348T3 (en) 2013-11-22 2021-10-11 Mina Therapeutics Ltd MAP C / EBP-ALPHA FOR ACTIVATION OF RNA COMPOSITIONS AND METHODS OF USE
PT3134506T (en) 2014-04-25 2019-10-31 Translate Bio Inc Methods for purification of messenger rna
CN108096189A (en) * 2016-11-25 2018-06-01 国家纳米科学中心 A kind of elaioplast nanometer particle and its pharmaceutical composition and application
EP3585417B1 (en) 2017-02-27 2023-02-22 Translate Bio, Inc. Method of making a codon-optimized cftr mrna
MA49138A (en) 2017-05-16 2020-03-25 Translate Bio Inc TREATMENT OF CYSTIC FIBROSIS BY ADMINISTRATION OF CODON-OPTIMIZED MRNA CODING FOR CFTR
EP4183882A1 (en) 2017-09-08 2023-05-24 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
AU2019325702A1 (en) 2018-08-24 2021-02-25 Translate Bio, Inc. Methods for purification of messenger RNA
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
CN110638759A (en) * 2019-10-29 2020-01-03 珠海丽凡达生物技术有限公司 A preparation for in vitro transfection and in vivo mRNA delivery
KR20230124927A (en) 2020-11-25 2023-08-28 아카제라 메디신즈, 인크. Lipid Nanoparticles for Delivery of Nucleic Acids, and Related Methods of Use
US20240175033A1 (en) 2021-03-26 2024-05-30 Mina Therapeutics Limited TMEM173 saRNA Compositions and Methods of Use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US20030035829A1 (en) * 1997-07-24 2003-02-20 Townsend And Townsend And Crew Liposomal compositions for the delivery of nucleic acid catalysts
JP5117648B2 (en) * 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Cationic PEG lipids and methods of use.

Also Published As

Publication number Publication date
EP1328254B1 (en) 2007-02-21
CA2426244A1 (en) 2002-05-02
ATE354350T1 (en) 2007-03-15
DE60126801T2 (en) 2007-12-06
JP2004511572A (en) 2004-04-15
WO2002034236A2 (en) 2002-05-02
DE60126801D1 (en) 2007-04-05
WO2002034236A3 (en) 2003-01-09
EP1328254A2 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
AU2002214854A1 (en) Lipid formulations for target delivery
WO2006012502A3 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2004064769A3 (en) Methods for making and using topical delivery agents
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
EP1149115A4 (en) METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2000062813A3 (en) Cationic peg-lipids and methods of use
EP1355634B8 (en) Sn-38 lipid complexes and methods of use
WO2004090108A3 (en) Irna conjugates
AU2001263106A1 (en) Navigation system, method and software for foot travel
WO2001082932A3 (en) Methods and compositions for enhancing cellular function through protection of tissue components
AU2001232377A1 (en) The method of advertisement using online games
WO2003077861A3 (en) Water-based delivery systems
WO2004091578A3 (en) Novel encochleation methods, cochleates and methods of use
WO2006013369A3 (en) Compositions forming non-lamellar dispersions
PL1643833T3 (en) Agrochemical formulations
WO2003000233A3 (en) Delivery of small hydrophilic molecules packaged into lipid vesicles
WO2007117550A3 (en) Methods for coacervation induced liposomal encapsulation and formulations thereof
BR0105457A (en) Therapeutic combinations to stimulate bone growth
WO2004067063A3 (en) Improved formulations for transmucosal vaginal delivery of bisphosphonates
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2004045491A3 (en) Targeted double stranded rna mediated cell killing
CA2483916A1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
BR0112258A (en) Poorly Water Soluble Drug Delivery System
WO2003035032A3 (en) New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications